

Brandes Investment Partners
European Equity Strategy Notes
Third Quarter 2024 (July 1 – September 30, 2024)

The Brandes European Equity Strategy rose 12.10% net of fees and 12.29% gross of fees, outperforming its benchmark, the MSCI Europe Index, which increased 6.58% in the quarter, and the MSCI Europe Value Index, which appreciated 9.52%.

Annualized total return as of September 30, 2024	1-year	5-year	10-year
Brandes European Equity Composite (net)	36.38%	13.25%	7.21%
Brandes European Equity Composite (gross)	37.32%	14.01%	7.89%
MSCI Europe Index	25.23%	8.89%	5.59%

Past performance is not a guarantee of future results. One cannot invest directly in an index. Returns include reinvestment of all dividends and are reduced by any applicable foreign withholding taxes, without provisions for income taxes, if any.

Positive Contributors

Leading contributors included holdings in health care, notably Spain-based biotechnology firm Grifols, medical equipment companies U.K.-based Smith & Nephew and Netherlands-based Koninklijke Philips, and German health care services company Fresenius SE.

In July, Grifols confirmed that the founding family, which controls 30% of the company, and Brookfield, a multinational Canadian alternative investment fund, are evaluating a potential joint takeover bid for the entire business. The structure and pricing remain unclear, but the market reacted positively to their proposal.

Geographically, holdings in the U.K. were major contributors. Aerospace and defense company Rolls-Royce continued to report improving earnings arising from the recovery in its aerospace end-markets. Other solid U.K.-based performers included consumer staples companies Tesco, J Sainsbury, and Marks and Spencer, as well as home retailer Kingfisher and construction company Balfour Beatty.

Relative to the benchmark, our underweight in technology stocks aided returns as technology-related companies were some of the weakest performers in the MSCI Europe Index.

Performance Detractors

The most notable detractors were in the financials sector. These included Spanish insurance company Linea Directa Aseguradora, and two small-cap banks: Slovenia-based Nova Ljubljanska Banka (NLB) and Austria-based Addiko Bank. Both banks saw their share prices decline after NLB scrapped its takeover offer for Addiko.

Other detractors included Netherlands-based beverage company Heineken Holdings and French luxury goods firm Kering.

Heineken's shares declined after the company took an impairment charge for its stake in China Resources Beer, reflecting a weaker consumer environment in China. Meanwhile, Kering remained under pressure as it worked to revitalize its Gucci business. Although the shares rebounded toward the end of the quarter due to the potential for Chinese stimulus, the increase was not enough to fully offset the earlier decline.

Select Activity in the Quarter

The investment committee divested French auto manufacturer Renault, U.K. consumer products company Unilever, and financial brokerage and advisory firm Willis Towers Watson after they reached our estimates of intrinsic value.

We initially bought Ireland-domiciled Willis Towers Watson (WTW) just over a year ago because its share price had underperformed the broader market (MSCI Europe) following its failed merger with Aon. We believed that the company offered an appealing investment opportunity given its reliable cash-flow generation, solid balance sheet, and attractive valuation. We also believed it had the potential to improve its margins closer to its insurance brokerage peers.

During the past year, the company has generated improved growth and has seen margin expansion and increased free-cash-flow generation. While our estimate of WTW's intrinsic value increased, the share price increased more significantly. When it reached our updated intrinsic value estimate, we sold our position.

The investment committee used the proceeds from these sales to add to several existing holdings, including recent purchase Infineon, as well as some of the detractors mentioned for the quarter.

Year-to-Date Briefing

The Brandes European Equity Strategy rose 21.8% net of fees and 22.50% gross of fees, outperforming its benchmark, the MSCI Europe Index, which increased 12.77% in the nine months ended September 30, 2024, and the MSCI Europe Value Index, which appreciated 13.81%.

While value outperformance provided a better backdrop for the strategy, it was stock selection across nearly all sectors that drove the relative returns. Investments in financials, industrials, and consumer staples have been the most noteworthy contributors. These were led by Rolls-Royce, Ireland-based consumer staples company Greencore, Italy's Intesa Sanpaolo, and Nova Ljubljanska Banka. Other contributors included communication services firms Magyar Telekom (Hungary) and Millicom International (Luxembourg), as well as medical equipment company Koninklijke Philips.

Several investments in health care detracted from returns, most notably French pharmaceutical Euroapi and Spain's Grifols. Grifols' stock declined (mainly in the first quarter) following a short seller's report that questioned the company's debt, accounting, and corporate governance practices. As mentioned, Grifols' shares did rebound during the third quarter, and we continue to see a meaningful upside potential in owning the company.

Other detractors included Kering and Heineken Holdings, as well as Swiss watchmaker Swatch.

Current Positioning

The Brandes European Equity Strategy holds key overweight positions in consumer staples and communication services, while maintaining significant underweights in technology and industrials. While the strategy remains underweight in industrials, our exposure to that sector increased this year as we have uncovered several new opportunities that we believe have attractive return potential. Our weight to financials has decreased as we have pared and sold some companies that performed well this year and, as a result, their margin of safety (the discount of market price to our estimate of intrinsic value) narrowed. Accordingly, we are now underweight the sector versus the MSCI Europe Index.

Geographically, the portfolio's largest allocations continue to be in France and the United Kingdom. It remains underweight in Switzerland and has no exposure to companies in the Nordic Region. While we maintain our lower weighting to Germany relative to the benchmark, our underweight has narrowed this year with the acquisition of Infineon and Deutsche Post. We believe the differences between the MSCI Europe Index and our strategy make it an excellent complement and diversifier to passive and growth-oriented options.

As of September 30, value stocks (MSCI Europe Value) continued to trade in the least-expensive decile relative to growth (MSCI Europe Growth) since the inception of the style indices, across various valuation measures, including price/earnings, price/cash flow, and enterprise value/sales. Historically, such discount levels have often signaled attractive subsequent returns for value stocks. We find this encouraging because the Brandes European Equity Strategy—guided by our value philosophy and process—has tended to outperform the value index when it surpassed the benchmark.

Looking ahead, we remain optimistic about the long-term prospects of the companies held in the Brandes European Equity Strategy.

Term definitions: <https://www.brandes.com/termdefinitions>

The MSCI Europe Index with net dividends captures large and mid cap representation of developed market countries in Europe.

The MSCI Europe Value Index captures large and mid cap securities across developed Europe exhibiting value style characteristics, defined using book value to price, 12-month forward earnings to price, and dividend yield.

The MSCI Europe Growth Index captures large and mid cap securities across developed Europe exhibiting growth style characteristics, defined using long-term forward earnings per share (EPS) growth rate, short-term forward EPS growth rate, current internal growth rate, long-term historical EPS growth trend, and long-term historical sales per share growth trend.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. European and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

United States: Issued by Brandes Investment Partners, L.P., 4275 Executive Square, 5th Floor, La Jolla, CA 92037.

Singapore/Asia: FOR INSTITUTIONAL/ACCREDITED INVESTOR USE ONLY. Issued by Brandes Investment Partners (Asia) Pte Ltd., The Gateway West, 150 Beach Road, #35-51, Singapore 189720. Company Registration Number 201212812M. ARBN:164 952 710. This document is for "institutional investors" or "accredited investors" as defined under the Securities and Futures Act, Chapter 289 of Singapore and may not be distributed to any other person. This document is being provided for information purposes only. Incorporated in Singapore in 2012, Brandes Investment Partners (Asia) Pte Ltd (Brandes Asia) provides portfolio management services to clients in Asia (as permitted under local law). Brandes Investment Partners, L.P., a U.S. registered investment adviser and a sister entity to Brandes Asia, provides research, portfolio construction and other support to Brandes Asia.

Canada: FOR REGISTERED DEALERS AND THEIR REGISTERED SALESPERSONS' USE ONLY. NOT FOR DISTRIBUTION TO INVESTORS. Distributed by Brandes Investment Partners & Co., 6 Adelaide Street East, Suite 900, Toronto, ON, M5C 1H6. This communication is for information purposes only and should not be regarded as a sales communication or as advice regarding any financial product or services.